BioCanCell Announces Terms of $25 Million Funding Round
January 23, 2018 08:00 ET
|
BioCanCell Ltd.
JERUSALEM, Jan. 23, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL) (the “Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Shareholders Turn Down Tender Offer to Take BioCanCell Private
December 28, 2017 09:23 ET
|
BioCanCell Ltd.
JERUSALEM, Dec. 28, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round
December 11, 2017 16:01 ET
|
BioCanCell Ltd.
JERUSALEM, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer
November 15, 2017 16:01 ET
|
BioCanCell Ltd.
JERUSALEM, Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
BioCanCell Announces Exploration of Funding Round Conditioned on a Going Private Transaction and Business Development Update
October 30, 2017 07:00 ET
|
BioCancell Ltd.
JERUSALEM, Oct. 30, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
BioCanCell Announces Appointment of Ms. Ruti Alon to Board of Directors
August 14, 2017 07:00 ET
|
BioCancell Ltd.
JERUSALEM, Aug. 14, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...